MX2020002644A - Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas. - Google Patents

Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas.

Info

Publication number
MX2020002644A
MX2020002644A MX2020002644A MX2020002644A MX2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A MX 2020002644 A MX2020002644 A MX 2020002644A
Authority
MX
Mexico
Prior art keywords
slc14a1
solute carrier
carrier family
variants
disclosure
Prior art date
Application number
MX2020002644A
Other languages
English (en)
Inventor
Dostal Tonya Teslovich
Joshua Backman
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020002644A publication Critical patent/MX2020002644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La descripción proporciona moléculas de ácido nucleico, que incluyen ADNc, que comprenden una alteración que codifica proteínas del miembro 1 de la familia 14 portadora de solutos (SLC14A1) que se relacionan con la protección contra la enfermedad de las arterias coronarias (EAC). La descripción también proporciona métodos para clasificar sujetos en riesgo de desarrollar una afección de coagulación, en función de la identificación de dichas alteraciones.
MX2020002644A 2017-09-07 2018-09-06 Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas. MX2020002644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555440P 2017-09-07 2017-09-07
PCT/US2018/049674 WO2019051033A1 (en) 2017-09-07 2018-09-06 VARIANTS OF MEMBER 1 OF SOLUT TRANSPORTER FAMILY 14 (SLC14A1) AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020002644A true MX2020002644A (es) 2020-10-07

Family

ID=63714031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002644A MX2020002644A (es) 2017-09-07 2018-09-06 Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas.

Country Status (12)

Country Link
US (2) US20190071683A1 (es)
EP (1) EP3679060A1 (es)
JP (1) JP2020536500A (es)
KR (1) KR20200062224A (es)
CN (1) CN111278851A (es)
AU (1) AU2018330458A1 (es)
CA (1) CA3074682A1 (es)
IL (1) IL272981A (es)
MX (1) MX2020002644A (es)
RU (1) RU2020112313A (es)
SG (1) SG11202001792UA (es)
WO (1) WO2019051033A1 (es)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
JPH10510700A (ja) 1993-06-04 1998-10-20 アメリカ合衆国 アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
EP1836322B8 (en) * 2005-01-13 2017-01-11 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
US9234897B2 (en) * 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
EP1825850A1 (en) * 2006-02-24 2007-08-29 DSMIP Assets B.V. Use of resveratrol and derivatives thereof for promoting the wellness state in mammals
WO2008003826A1 (en) * 2006-07-07 2008-01-10 Oy Jurilab Ltd Novel genes and markers in essential arterial hypertension
JP2009039040A (ja) * 2007-08-09 2009-02-26 Otsuka Pharmaceut Factory Inc ヒトにおけるＳＬＣトランスポーターのｍＲＮＡの測定方法、そのためのプローブ及びキット
WO2012095872A1 (en) * 2011-01-13 2012-07-19 Decode Genetics Ehf Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2015039972A1 (en) * 2013-09-17 2015-03-26 Bayer Pharma Aktiengegesellschaft Modulators of slc22a13
CN108779181A (zh) * 2015-10-16 2018-11-09 国立输血研究院 生产红细胞蛋白质的方法

Also Published As

Publication number Publication date
RU2020112313A (ru) 2021-10-08
IL272981A (en) 2020-04-30
KR20200062224A (ko) 2020-06-03
AU2018330458A1 (en) 2020-03-19
JP2020536500A (ja) 2020-12-17
CA3074682A1 (en) 2019-03-14
SG11202001792UA (en) 2020-03-30
EP3679060A1 (en) 2020-07-15
US20190071683A1 (en) 2019-03-07
WO2019051033A1 (en) 2019-03-14
RU2020112313A3 (es) 2022-02-24
US20210230609A1 (en) 2021-07-29
CN111278851A (zh) 2020-06-12

Similar Documents

Publication Publication Date Title
Stoka et al. Lysosomal cathepsins and their regulation in aging and neurodegeneration
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
BR112017015888A2 (pt) dispositivo, adesivo de eletromiografia, e método para determinar e/ou monitorar o esforço respiratório de um indivíduo; e programa de computador
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
Paul et al. A CHIPotle in physiology and disease
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
BR112017012451A2 (pt) sistemas de monitoramento físico
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
MX2021015165A (es) Metodos de procesamiento de un fluido que incluye una proteina terapeutica recombinante y uso de los mismos.
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
WO2014197816A8 (en) Stimulus responsive nanocomplexes and methods of use thereof
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
EP3640143A4 (en) AIRCRAFT HOVER ASSISTANCE SYSTEM AND AIRCRAFT WITH IT
EP3471600A4 (en) METHODS AND SYSTEMS FOR SCREENING AND MONITORING MORBUS ALZHEIMER WITH THE KING DEVICK TEST
MX2020002644A (es) Variantes del miembro 1 de la familia 14 del grupo portador de solutos (slc14a1) y usos de estas.
EP4253960A3 (en) Materials and methods for assessing cancer risk and treating cancer
Ocakoğlu et al. The shape of the external human ear: a geometric morphometric study
HK1258207A1 (zh) 基於鉴别和改善肝功能障碍来诊断和治疗帕金森病
HUE062537T2 (hu) Peptidek diabetes és társult betegségek kezelésére
WO2017059276A8 (en) Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
Brinster et al. Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article" Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015; 82: 200-2
MX2022007826A (es) Variantes de la adenilato ciclasa 7 (adcy7) y usos de estas.
Crawford Commentary on" Rupestonic acid derivative YZH-106 suppresses influenza virus replication by activation of heme oxygenase-1-mediated interferon response" by Ma et al.[Free Radic. Biol. Med. 96 (2016) 347-361]